TISIDB

Summary
Symbol	NTN1
Name	netrin 1
Aliases	NTN1L; Netrin-1; epididymis tissue protein Li 131P; netrin 1, mouse, homolog of
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Secreted, extracellular space, extracellular matrix
Domain	PF00053 Laminin EGF domain PF00055 Laminin N-terminal (Domain VI) PF01759 UNC-6/NTR/C345C module
Function	Netrins control guidance of CNS commissural axons and peripheral motor axons. Its association with either DCC or some UNC5 receptors will lead to axon attraction or repulsion, respectively. It also serve as a survival factor via its association with its receptors which prevent the initiation of apoptosis. Involved in tumorigenesis by regulating apoptosis.

> Gene Ontology [ TOP ]
Biological Process	GO:0001558 regulation of cell growth GO:0001764 neuron migration GO:0006929 substrate-dependent cell migration GO:0006930 substrate-dependent cell migration, cell extension GO:0007265 Ras protein signal transduction GO:0007266 Rho protein signal transduction GO:0007409 axonogenesis GO:0007411 axon guidance GO:0007423 sensory organ development GO:0008361 regulation of cell size GO:0010720 positive regulation of cell development GO:0010721 negative regulation of cell development GO:0010769 regulation of cell morphogenesis involved in differentiation GO:0010770 positive regulation of cell morphogenesis involved in differentiation GO:0010771 negative regulation of cell morphogenesis involved in differentiation GO:0010975 regulation of neuron projection development GO:0010976 positive regulation of neuron projection development GO:0010977 negative regulation of neuron projection development GO:0016049 cell growth GO:0022604 regulation of cell morphogenesis GO:0022612 gland morphogenesis GO:0030031 cell projection assembly GO:0030307 positive regulation of cell growth GO:0030308 negative regulation of cell growth GO:0030516 regulation of axon extension GO:0030517 negative regulation of axon extension GO:0030879 mammary gland development GO:0031345 negative regulation of cell projection organization GO:0031346 positive regulation of cell projection organization GO:0032488 Cdc42 protein signal transduction GO:0032535 regulation of cellular component size GO:0033564 anterior/posterior axon guidance GO:0035239 tube morphogenesis GO:0040017 positive regulation of locomotion GO:0040023 establishment of nucleus localization GO:0042471 ear morphogenesis GO:0042472 inner ear morphogenesis GO:0043583 ear development GO:0045665 negative regulation of neuron differentiation GO:0045666 positive regulation of neuron differentiation GO:0045773 positive regulation of axon extension GO:0045926 negative regulation of growth GO:0045927 positive regulation of growth GO:0048562 embryonic organ morphogenesis GO:0048568 embryonic organ development GO:0048588 developmental cell growth GO:0048638 regulation of developmental growth GO:0048639 positive regulation of developmental growth GO:0048640 negative regulation of developmental growth GO:0048667 cell morphogenesis involved in neuron differentiation GO:0048675 axon extension GO:0048732 gland development GO:0048839 inner ear development GO:0050768 negative regulation of neurogenesis GO:0050769 positive regulation of neurogenesis GO:0050770 regulation of axonogenesis GO:0050771 negative regulation of axonogenesis GO:0050772 positive regulation of axonogenesis GO:0051272 positive regulation of cellular component movement GO:0051640 organelle localization GO:0051647 nucleus localization GO:0051656 establishment of organelle localization GO:0051961 negative regulation of nervous system development GO:0051962 positive regulation of nervous system development GO:0060443 mammary gland morphogenesis GO:0060560 developmental growth involved in morphogenesis GO:0060562 epithelial tube morphogenesis GO:0060603 mammary gland duct morphogenesis GO:0061180 mammary gland epithelium development GO:0061387 regulation of extent of cell growth GO:0061564 axon development GO:0090066 regulation of anatomical structure size GO:0090596 sensory organ morphogenesis GO:0097485 neuron projection guidance GO:1990138 neuron projection extension GO:2000147 positive regulation of cell motility
Molecular Function	-
Cellular Component	GO:0005578 proteinaceous extracellular matrix GO:0005604 basement membrane GO:0044420 extracellular matrix component

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04360 Axon guidance
Reactome	R-HSA-422475: Axon guidance R-HSA-1500931: Cell-Cell communication R-HSA-418885: DCC mediated attractive signaling R-HSA-376172: DSCAM interactions R-HSA-1266738: Developmental Biology R-HSA-418886: Netrin mediated repulsion signals R-HSA-373752: Netrin-1 signaling R-HSA-418890: Role of second messengers in netrin-1 signaling

Summary
Symbol	NTN1
Name	netrin 1
Aliases	NTN1L; Netrin-1; epididymis tissue protein Li 131P; netrin 1, mouse, homolog of
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between NTN1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	NTN1
Name	netrin 1
Aliases	NTN1L; Netrin-1; epididymis tissue protein Li 131P; netrin 1, mouse, homolog of
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of NTN1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	NTN1
Name	netrin 1
Aliases	NTN1L; Netrin-1; epididymis tissue protein Li 131P; netrin 1, mouse, homolog of
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of NTN1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.653	0.0396
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.97	0.0771
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.416	0.372
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.416	0.356
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.507	0.732
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.303	0.873
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.44	0.448
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.425	0.0919
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.763	0.42
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.638	0.24
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.71	0.324
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.109	0.686

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of NTN1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	25	0	25	0.222
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	NTN1
Name	netrin 1
Aliases	NTN1L; Netrin-1; epididymis tissue protein Li 131P; netrin 1, mouse, homolog of
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NTN1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	NTN1
Name	netrin 1
Aliases	NTN1L; Netrin-1; epididymis tissue protein Li 131P; netrin 1, mouse, homolog of
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NTN1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NTN1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	NTN1
Name	netrin 1
Aliases	NTN1L; Netrin-1; epididymis tissue protein Li 131P; netrin 1, mouse, homolog of
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NTN1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	NTN1
Name	netrin 1
Aliases	NTN1L; Netrin-1; epididymis tissue protein Li 131P; netrin 1, mouse, homolog of
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of NTN1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	NTN1
Name	netrin 1
Aliases	NTN1L; Netrin-1; epididymis tissue protein Li 131P; netrin 1, mouse, homolog of
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between NTN1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	NTN1
Name	netrin 1
Aliases	NTN1L; Netrin-1; epididymis tissue protein Li 131P; netrin 1, mouse, homolog of
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting NTN1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse NTN1